key: cord-0726282-xgfk6txz authors: Read, Scott A; Obeid, Stephanie; Ahlenstiel, Chantelle; Ahlenstiel, Golo title: The Role of Zinc in Antiviral Immunity date: 2019-04-22 journal: Adv Nutr DOI: 10.1093/advances/nmz013 sha: 95d7d2dd0ee25084c9d6f284bd5cb3ae1065157c doc_id: 726282 cord_uid: xgfk6txz Zinc is an essential trace element that is crucial for growth, development, and the maintenance of immune function. Its influence reaches all organs and cell types, representing an integral component of approximately 10% of the human proteome, and encompassing hundreds of key enzymes and transcription factors. Zinc deficiency is strikingly common, affecting up to a quarter of the population in developing countries, but also affecting distinct populations in the developed world as a result of lifestyle, age, and disease-mediated factors. Consequently, zinc status is a critical factor that can influence antiviral immunity, particularly as zinc-deficient populations are often most at risk of acquiring viral infections such as HIV or hepatitis C virus. This review summarizes current basic science and clinical evidence examining zinc as a direct antiviral, as well as a stimulant of antiviral immunity. An abundance of evidence has accumulated over the past 50 y to demonstrate the antiviral activity of zinc against a variety of viruses, and via numerous mechanisms. The therapeutic use of zinc for viral infections such as herpes simplex virus and the common cold has stemmed from these findings; however, there remains much to be learned regarding the antiviral mechanisms and clinical benefit of zinc supplementation as a preventative and therapeutic treatment for viral infections. Zinc deficiency was first recognized by Prasad et al. >50 y ago in a malnourished group of individuals presenting with hepatosplenomegaly, dwarfism, hypogonadism, and an elevated risk of infection (1) . Unbeknownst to Dr. Prasad and his colleagues at the time, their discovery would highlight the importance of zinc as an integral component of human physiology, and inspire decades of zinc research. It is now understood that zinc is the second-most abundant trace metal in the human body after iron, and an essential component of protein structure and function. Importantly, zinc is a structural constituent of ∼750 zinc-finger transcription factors (2) enabling gene transcription, and is a catalytic component of approximately 2000 enzymes, encompassing all 6 classes (hydrolase, transferase, oxido-reductase, ligase, lyase, and isomerase) (3) . Hence, zinc is biologically essential for cellular processes, including growth and development, as well as DNA synthesis and RNA transcription (4) . The global prevalence of zinc deficiency is estimated to range from ∼17% to 20% (5, 6) , with the vast majority occurring in developing countries of Africa and Asia. Although significantly less common in high-income nations, zinc deficiency occurs most frequently in the elderly, vegans/vegetarians, and individuals with chronic disease such as liver cirrhosis (7) or inflammatory bowel disease (8) . Importantly, zinc deficiency results in a compromised immune system, as evidenced by thymic atrophy, lymphopenia, and defective lymphocyte responses in animal studies (9) . These data underscore the importance of zinc nutrition, particularly in underdeveloped countries where the risk of infection is heightened because of poor sanitation, public health, and vaccination strategies (5) . This review focuses on the role of zinc as an essential micronutrient that is required to mount an effective antiviral response. Although zinc possesses direct antiviral properties (e.g. influenza), it is also critical in generating both innate and acquired (humoral) antiviral responses. To complicate matters, zinc is an integral component of many viral enzymes, proteases, and polymerases, highlighting the importance of regulating cellular and systemic zinc distribution to inhibit viral replication and dissemination. Metallothioneins are small, cysteine-rich proteins capable of binding divalent cations such as zinc and copper. As vessels for much of the labile intracellular zinc pool, metallothioneins possess numerous functions through their ability to bind and release metals from their thiol groups. These include storage and transfer of zinc ions and heavy metal detoxification, as well as involvement in oxidative stress, apoptosis, and immune responses (23) . Humans express 4 metallothionein isoforms (MT1-4), including the ubiquitously expressed MT1 and MT2 genes (MT1A, B, E, F, G, H, I, J, L, M, X, MT2A), as well as MT3 and MT4 whose expression is limited, and function remains poorly understood (24) . Importantly, MT1 and 2 gene expression is extremely responsive to zinc, and therefore serves as an ideal indicator of an individual's zinc status (25) . Upon taking a zinc supplement, for example, an increase in protein-bound zinc in the bloodstream is internalized by cells in various tissues and organs through the ZIP transporters. In response to increased intracellular zinc, the metal-responsive transcription factor (MTF1) becomes active, and binds the metal responsive element in metallothionein gene promoters to upregulate their transcription (26) . Although there are additional stimuli that influence metallothionein expression, this primarily occurs in a zincdependent fashion. Oxidative stress, for example, induces zinc release from metallothioneins as a mechanism to reduce reactive oxygen species generated by mitochondrial dysfunction or viral infection (26) . Zinc released from metallothioneins binds MTF1 to stimulate additional metallothionein expression. It should be noted that metallothioneins, although highly responsive to zinc, have long been classified as interferon stimulated genes (ISGs) (27) . IFNs are immunostimulatory cytokines secreted from infected cells and nearby immune cells that induce the expression of hundreds of antiviral genes. They possess diverse roles including chemoattraction, immune cell activation, and direct antiviral activity. In response to IFNs, we suggest that there are 2 mechanisms of metallothionein induction. Most ISGs possess binding sites for STAT-or IFN regulatory factor (IRF) transcription factormediated expression, as is the case for MT1X and MT2A (28, 29) . Other metallothioneins such as MT1F and MT1G do not possess known IFN regulatory regions in their promoters, but are instead more sensitive to zinc (28) . IFNs stimulate an influx of zinc into the target cell, as is the case with some inflammatory cytokines such as IL-6, which in turn drives metallothionein expression. Because metallothioneins possess such a diverse functional repertoire, their specific roles during viral infection remain undefined. However, both in vitro and in vivo studies have made it abundantly clear that metallothioneins are induced by viruses. The mechanisms often remain undefined; however, metallothionein expression has been attributed to zinc influx or redistribution (19, 28) , by viral means, cytokine exposure, or oxidative stress (30) . Metallothionein upregulation has been observed in response to measles virus (31) , influenza (31, 32) , HIV (33), hepatitis C virus (HCV) (34) , and coxsackie virus (35) , among others. In the case of HIV, zinc appears to be the key driver of metallothionein expression to favor viral persistence. HIVinfected monocytes demonstrate a significant increase in both MT1 gene expression as well as intracellular zinc (33) . Elevated intracellular zinc increases monocyte resistance to apoptosis via inhibition of caspase 3 activation [as has been reported previously (36) ], thus providing a reservoir for HIV replication. The role of metallothioneins remains unclear in this study; however, they have been described as negative regulators of apoptosis, albeit not through direct caspase 3 inhibition (37) . Zinc and metallothioneins also facilitate human cytomegalovirus (HCMV) replication by activating the immediate-early HCMV promoter (38, 39) . Kanekiyo et al. demonstrated that both zinc and metallothionein overexpression increased NF-κB binding in the HCMV promoter. Because no complex was detected between metallothionein and NF-κB, it was suggested that metallothioneins served as a zinc donor necessary for NF-κB binding. In addition, as NF-κB transcription factors are known potent activators of HIV and HSV replication, and several other viruses (40) , metallothioneins may be proviral. Zinc has also been reported to inhibit NF-κB in numerous studies (41) (42) (43) . Despite these contrasting data, Kim et al. have bridged these inconsistencies, demonstrating that MT2A can serve as a sink for excess zinc (44) , thus limiting its proximity to NF-κB and favoring NF-κB-mediated transcription. In the case of HCV infection, metallothioneins possess an antiviral role. Using a pan-metallothionein siRNA to knockdown all MT1 and 2 genes, we demonstrated both an increase in HCV replication and a decrease in intracellular zinc content in vitro (34) . Interestingly, although ZnSO 4 can reduce HCV replication, this effect was ablated when metallothionein genes were knocked down. These data suggest that metallothioneins are either 1) directly antiviral, potentially by sequestering zinc away from viral metalloproteins such as HCV NS5A (45), or 2) indirectly antiviral by acting as zinc chaperones and facilitating antiviral signaling. Further, metallothioneins possess antiviral properties against other viruses as well, as demonstrated in an antiviral screen of 380 human ISGs performed by Schoggins et al. (46) . Overexpression of multiple members of the MT1 family inhibited replication of flaviviruses including yellow fever virus and HCV, as well as the alphavirus Venezuelan equine encephalitis virus. This effect was not observed in West Nile virus, and Chikungunya virus. These data indicate that metallothioneins, like many ISGs, are selectively antiviral, perhaps reflecting specific viral zinc requirements during replication. This is particularly evident for HIV, which demonstrated an increase in viral replication as a result of metallothionein overexpression in the Schoggins et al. ISG screen (46) , validating previous works (33) . Many studies have evaluated the efficacy of zinc as an antiviral agent in vitro. Unfortunately, zinc concentrations used to assess antiviral activity often far exceed physiological concentrations. Human plasma zinc, for example, ranges from approximately 10 to 18 μM (47), whereas antiviral concentrations of zinc can reach into mM concentrations (48) . Intracellular zinc concentrations range from 10s to 100s of μM, but are significantly buffered by zinc-binding proteins such as metallothioneins, rendering free zinc concentrations at picomolar to low nanomolar concentrations (49, 50) . The antiviral properties of zinc are certainly virus-specific, but it would appear that zinc ion availability plays a significant role in the antiviral efficacy of zinc (51) . Here we describe the role of zinc as a virus-specific antiviral: both in vitro mechanistic studies, as well as human-based clinical trials using zinc supplementation. In vitro and in vivo studies are summarized in Tables 1 and 2, respectively. The effect of zinc on HSV-1 and -2 has been studied for >40 y, with in vitro studies suggesting that zinc plays an inhibitory role on almost every aspect of the viral life cycle: viral polymerase function (52) , protein production and processing (53) , and free virus inactivation (48, 54) . Although these studies were performed >20 y ago, a more recent study using the zinc ionophore pyrithione demonstrated a reduction in HSV replication from reduced NF-κB activation by interfering with the protein ubiquitination pathway (41) . Unfortunately, no recent experimental data can demonstrate with any certainty the mechanism by which zinc inhibits HSV infection. Nonetheless, in vivo studies in mice and humans have shown a significant reduction of infection and disease burden. Mouse studies performing intravaginal zinc inoculation in liquid (55) or gel (56) form both resulted in significant reductions in HSV-2 infection. Several topical zinc application studies have been performed in humans, which demonstrated a significantly reduced recurrence and duration of infection (outbreak) (57) (58) . The efficacy of topical application, together with in vitro results (48, 54) , suggest that free zinc may indeed coat HSV virions, thus preventing infection. Further research into this molecular mechanism is warranted. Apart from HCMV mentioned above, the effect of zinc on other members of the Herpesviridae family remains unknown because of a lack of clinical data. Mechanistically, zinc ions have been shown to inhibit Varicella-Zoster virus by inactivating free virus in vitro (59) . Both HSV and Varicella-Zoster virus belong to the Alphaherpesvirinae subfamily, reflecting their genetic relatedness, and similar mechanism of inhibition. Sindbis virus Inhibition of viral particle production and polyprotein cleavage It was clear as early as 1974 that zinc possessed an inhibitory effect on picornovirus polyprotein processing (73) . Before 1980, zinc inhibition of picornovirus proteases from human rhinovirus isolates (73, 74) , encephalomyocarditis virus (62), poliovirus (61) , and foot and mouth disease virus (64, 65) had all been demonstrated. More recent studies using zinc ionophores have illustrated that zinc interferes with the autocatalytic processing of the viral protease 3CD pro into 3C pro in the picornavirus coxsackievirus B3, thus inhibiting processing of the viral polyprotein (107) . However, this was not the case for encephalomyocarditis virus, where zinc appeared to inhibit the tertiary structure within the viral polyprotein (107) . Together, these data suggest that zinc may interfere with proteolytic processing of the viral polyprotein because of misfolding, or through direct actions on the viral protease 3CD pro . Clinical studies using zinc supplementation are primarily limited to rhinovirus infection, and are often grouped with other "common cold" viruses such as influenza and coronaviruses. The majority of studies use zinc lozenges with various zinc formulations and concentrations, possibly explaining the large variability in results [extensively reviewed in (108) and (109)]. Importantly, the amount of ionic zinc present at the site of infection (oral and nasal mucosa) is highly correlated to the study outcome (51, 108) , and is dependent on the zinc formulation. At a physiological pH and 37 • C, zinc gluconate for example, releases high amounts of ionic zinc, whereas zinc aspartate releases none (108) . Upon examining only the relevant studies where high doses of ionic zinc were used, a clear reduction in cold duration of 42% was calculated (109) . Whether this was caused by viral inhibition, improved local immune response, or an amelioration of symptoms remains uncertain. Few studies have examined the antiviral effects of zinc on other respiratory viruses. In vitro replication of influenza (PR/8/34) is significantly inhibited by the addition of the zinc ionophore pyrrolidine dithiocarbamate (110) , perhaps through inhibition of the RNA-dependent RNA polymerase (RdRp), as had been suggested 30 y earlier (111) . In similar fashion, severe acute respiratory syndrome (SARS) coronavirus RdRp template binding and elongation was inhibited by zinc in Vero-E6 cells (60) . Moreover, zinc salts were shown to inhibit respiratory syncytial virus, even while zinc was incubated with HEp-2 cells only before infection, and then removed (72) . The authors suggest that this indicates an inhibitory mechanism similar to HSV by preventing viral membrane fusion; however, no measures were taken to assess changes in intracellular zinc content, nor inhibition of other aspects of the viral life cycle. Flaviviruses represent a number of insect-borne viruses including dengue and West Nile virus, as well as the hepatotrophic virus, HCV. The effect of zinc on insect-borne flaviviruses is scarce; however, in vitro studies by our group (34) and others (67) have demonstrated that zinc salts can reduce HCV replication (∼50% at 100 μM ZnSO 4 ), perhaps by inhibiting the HCV RdRp, as shown in E. coli [half maximal inhibitory concentration (IC50) ∼60 μM] (66) . Although this is a potential mechanism, it has not been examined in eukaryotic cells in which zinc homeostasis is significantly different. If left untreated, HCV becomes a chronic hepatic infection in around two-thirds of individuals (112) , resulting in a significant reduction in plasma zinc (113) . Consequently, zinc supplementation in HCV studies have focused on improved patient outcomes, particularly decreased liver inflammation, and enhanced response to antiviral treatment. Supplementation with 150 mg/d polaprezinc (a bioavailable zinc l-carnosine chelate) has been shown to reduce markers of hepatic inflammation alanine aminotransferase and aspartate aminotransferase alone (105) , and in combination with the antiviral treatment IFN-α (106) . Moreover, polaprezinc significantly improved the rate of viral clearance, particularly in patients with lower viral loads at baseline (102) . The mechanisms underlying these observations remain uncertain; however, are likely a combination of direct antiviral effects and strengthening of the antiviral response. Zinc supplementation and the antiviral response is reviewed below. Like flaviviruses, togaviruses primarily consist of arthropodborne viruses such as Semliki Forest virus, Western equine encephalitis virus, and Chikungunya virus. Viral infection occurs by receptor-mediated endocytosis, followed by fusion of virus and endosomal membranes, and particle release into the cytoplasm (114) . Using liposome (76) , red blood cell (115) , and BHK-21 (77) cell model systems, zinc has been shown to efficiently inhibit membrane fusion of Semliki Forest virus and sindbis viruses. Zinc ions interfere with membrane fusion by binding to a specific histidine residue revealed on the viral E1 protein at low endosomal pH (77) . Unfortunately, the in vivo relevance of this model is unclear because of the high concentration of zinc (>1 mM) used. Notably, concentrated zinc is present in vesicular zincosomes that are thought to serve as intracellular zinc storage vesicles (116) . Similar to the mechanism used by macrophages to inhibit intracellular Mycobacterium spp., zincosome fusion to viral endosomes may inhibit key aspects of the viral life cycle such as togavirus membrane fusion. Retroviruses are named after their ability to transcribe RNA into DNA using their unique reverse transcriptase (RT), consequently allowing integration of retroviral DNA into the host genome. The integrated provirus can then establish a latent infection for the life of the host and is a major barrier to virus cure strategies, particularly for HIV-1 (117) . Similar to viral RdRps, zinc has also been identified as an inhibitor of retrovirus RTs (118, 119) . Fenstermacher and DeStefano demonstrated in 2011 that Zn 2+ cations can displace Mg 2+ ions from HIV-1 RT, promoting the formation of an excessively stable, but incredibly slow and inefficient replication complex (70) . Zinc was also shown to inhibit the HIV-1 protease in 1991 (68) , and to inhibit viral transcription in 1999 (69), but has received little attention since, with the exception of molecular simulation experiments that identified the zinc-binding sites at the catalytic aspartate-25 residue (120). As stated above, HIV can also stimulate zinc influx into monocytes (33) , which may appear contradictory based on its antiretroviral properties. Latently infected monocytes and macrophages, however, can act as viral reservoirs for HIV (121) , and could therefore benefit from zinc-mediated inhibition of cell death. In fact, unlike the majority of CD4 + T cells, low levels of replication in macrophages do not result in cell death (122) , making them a viable reservoir, in addition to long-lived resting CD4 + T cells, for viral recrudescence after cessation of antiretroviral treatment. Zinc deficiency is common in HIV-infected individuals, where it is associated with inflammation (123), immunological failure (124) , and death (125) . A recent Cochrane Review examined the role of micronutrient supplementation in people living with HIV (126) . Although a number of studies demonstrated beneficial effects of zinc supplementation, the majority were underpowered. The authors concluded that zinc supplementation probably increases blood zinc concentration (moderate certainty), and may increase CD4 + counts (low certainty). Unlike zinc supplements, prophylactic zinc gels have shown a substantial benefit to limit HIV infection in vivo. Complete protection against vaginal SHIV-RT (a simian HIV virus expressing the human RT) infection in macaques was obtained by pretreating animals with an antiviral gel containing 14 mM zinc acetate and 50 μM MIV-150, a reverse transcriptase inhibitor (127) . When used alone, zinc acetate is a potent antiviral, providing 66% protection against SHIV-RT vaginal infection (56) and an EC50 <100 μM in peripheral blood mononuclear cells against a range of HIV strains (128) . Importantly, zinc treatment did not affect viral titers in macaques that became infected, nor did it result in zinc resistant HIV mutants with conserved pol (RT) mutations. These data suggest that zinc may not interfere with the HIV RT, but instead inactivate free virus or prevent viral attachment/penetration as reported for HSV (48, 54) . HPVs are oncogenic viruses that infect basal epithelial cells, where they stimulate proliferation resulting in warts. Although cutaneous warts are usually self-limiting and harmless, mucosal strains of HPV (e.g. high risk HPV-16 and -18) are a primary cause of cervical cancers (129) . HPV oncoproteins E6 and E7 in particular, are significant drivers of cell proliferation and resistance to cell death by stimulating the degradation of tumor suppressor p53 and pRb, respectively [reviewed in (130) ]. Although nuclear zinc appears to enhance HPV replication (see Zinc homeostasis and viral infection), exogenous zinc treatment (CIZAR, zinc chloride and citric acid anhydrous) can effectively inhibit production of viral oncogenic proteins E6 and E7 (71) . The inhibition of E6 and E7 by zinc results in apoptosis of cervical carcinoma cells, as they regain the function of tumor suppressors p53 and pRb (71) . The mechanism by which zinc downregulates E6 and E7 expression is unknown, but may be preceded by a zinc-driven blockade in another component of the viral life cycle. It would appear that both topical and oral zinc supplementation strategies have proven tremendously effective for cutaneous and genital warts. Unfortunately, the vast majority of studies are either underpowered, lacking suitable controls, or single case studies. Nonetheless, a recent systematic review concluded that zinc supplementation was the most effective systemic treatment for cutaneous warts, when compared to other available options (131) . It should be noted, however, that individuals with persistent viral warts are often zincdeficient or have lower concentrations than their healthy counterparts (132) . In fact, studies demonstrating the most significant responses to zinc treatment had engaged patients that were primarily zinc-deficient (>70 μg/dL) (92, 94) . Nonetheless, 78% (94) and 100% (92) of patients showed clearance of lesions in response to oral zinc sulfate (10 mg/kg up to 600 mg/d) compared to 13% and 0% of the placebo group, respectively. Topical zinc formulations have also proved efficacious for treatment of viral warts. A small study using a 4-wk topical 10% zinc sulfate regimen for plane warts demonstrated an 86% response rate (6/7), compared to a 10% response rate (1/10) in the control group (93) . Recent work suggests that treatment of vaginal HPV infections with topical zinc formulations may benefit the millions of women that remain unvaccinated against HPV. A recent pilot study demonstrated that intravaginal infusion of 500 μM zinc citrate in women diagnosed with high-risk HPV resulted in a 64% clearance rate, compared to 15% in the control group (133) . Additional studies in mice have demonstrated that MZC, a formulation containing MIV-50, zinc acetate, and carrageenan, efficiently inhibited vaginal and anorectal HPV-16 pseudoviral particle infection (134) . In summary, it is evident that zinc possesses antiviral properties against a number of viral species. Although mechanistic studies are lacking, zinc appears to inhibit viral protease and polymerase enzymatic processes, as well as physical processes such as virus attachment, infection, and uncoating (Figure 1) . Unfortunately, these mechanisms have not been well scrutinized in clinical studies, where zinc may provide inexpensive and effective adjunct treatments for many viral infections. Ionic zinc possesses unique and distinct antiviral properties against a number of human viruses; however, the antiviral immune response led by IFNs is invariably required to clear infections. Zinc has been shown to contribute to a number of innate and adaptive immune signaling pathways that have been comprehensively reviewed recently (135) . As such, this review will focus specifically on the role of zinc in the immune response to viruses. Viral infections are recognized by a number of innate immune receptors termed pattern recognition receptors (PRRs). These include the cell surface and endosomal Tolllike receptors (TLRs), as well as a variety of cytosolic PRRs such as RIGI, MDA5, and IFI16 that primarily bind viral nucleic acids (136) . Following ligand binding, PRRs share a number of downstream signaling intermediates, that ultimately activate both inflammatory (NF-κB, AP1) and innate immune (IRF1/3/7) transcription factors. These transcription factors cooperate to induce expression of IFNs, of which there are 3 types: type I (IFN-α and IFN-β), type II (IFN-γ ), and type III (IFN-λs). Type I and III IFNs activate very similar antiviral signaling pathways; however, the type I IFN response is ubiquitous, whereas the type III IFN response is limited to a subset of immune cells, as well as epithelial cells of the liver, gastrointestinal, and pulmonary tracts (137) . Although both IFN types bind unique receptors, they activate a common signaling cascade where STAT1 and STAT2 heterodimerize and bind IRF9, followed by translocation into the nucleus and subsequent binding of the IFN-sensitive response element that is present in hundreds of gene promoters. As stated previously, these ISGs possess numerous roles including immune cell chemotaxis and activation, as well as numerous antiviral mechanisms to inhibit viral replication within infected and neighboring cells. Upon recognition of microbial antigens by TLRs, a rapid and transient influx of free zinc ions occurs. Interestingly, this has been demonstrated in response to viral stimuli, imiquimod, ssRNA40 (TLR7), and CpG (TLR9), but not polyI: C (TLR3) in the mouse macrophage RAW 264.7 cell line (138) . In response to TLR7 activation, zinc was shown to reduce the production of type I IFNs and ISGs CD80 and CD86. Based on results using other stimuli, the authors suggest that zinc can inhibit IRF3-, and perhaps IRF7dependent IFNB production, by limiting activation and/or nuclear translocation (138) . The role of the zinc influx in this context remains undefined, but may reflect a regulatory mechanism to prevent excessive IFN production. Although no direct inhibition of IRF signaling by zinc has been demonstrated, zinc can modulate a number of factors upstream of IRF activation. For example, the IκB kinase (IKK) members IKKα and IKKβ are inhibited by zinc, albeit at high concentrations of ∼0.5 μM (139). IKKα has been shown to activate IRF7 in response to TLR7/9 stimulation (140), whereas IKKβ (141), IKKε and TANK-binding kinase-1 (TBK1) (142) can activate IRF3 following TLR3 stimuli. Zinc can also stimulate expression of the deubiquitinating enzyme A20 (43) to inhibit the pathogen response. A20 is a regulator of NF-κB-(143), TLR3- (144) , and RIGI-mediated (145) IFN production, most likely by targeting PRR signaling components TIRdomain-containing adapter-inducing interferon-β (TRIF), TNF Receptor Associated Factor (TRAF) 2, and TRAF6. A20-deficient cells are hyper-responsive to viral infection, possess increased activation of NF-κB, IRF3, and IRF7, and improved viral clearance (146) . After pathogen recognition, NF-κB, AP1, and IRF3/7 bind IFN promoters to stimulate type I/III IFN production. Zinc plays a significant role in the response to IFNs by modulating secretion, cytokine potency, and receptor binding, as well as influencing signaling intermediates and pathway inhibitors. A recent study has demonstrated that intracellular zinc can reduce IFN secretion by destabilizing sortilin mRNA transcripts (147) . Sortilin is an endosomal protein that facilitates secretion of cytokines such as IFN-γ and IL6 (148) , and its depletion results in a significant reduction in secretion of IFN-α. Consequently, because sortilin ensures trafficking and secretion of numerous cytokines, it is possible that zinc also inhibits the secretion of other IFNs. Structural studies have demonstrated that zinc ions can mediate dimerization of IFNA molecules (149) . Nonetheless, apart from crystallization studies, dimers were difficult to generate despite using concentrated IFN (50 μM) and zinc (1 mM). It is therefore likely that the circulating active form of IFN-α is monomeric. A single study performed in 2001 showed that zinc can increase the antiviral activity of IFN-α 10-fold against rhinovirus challenge (150) . Although this study drew radical conclusions, antiviral activity was based on cytopathic effect alone, and its results have not been reproduced since. Moreover, zinc was added before viral infection, which is known to interfere with rhinovirus polyprotein processing (73, 74) , as reviewed above. Unlike type I IFNs, a recent study by our group has shown that zinc can inhibit IFN-λ3 signaling, most likely by preventing receptor binding and subsequent signaling (28) . Upon demonstrating in 2014 that metallothionein expression was IFNL genotype-dependent, and inversely associated with ISG expression in HCV (151), we showed that serum zinc was the driver of hepatic metallothionein expression. Although zinc had minimal effect on IFN-α signaling, it could almost ablate IFN-λ3 signaling at a concentration of 50 μM, resulting in a significant reduction in its antiviral activity (28) . Interestingly, we found no inhibition of IFN-λ1 activity using 50 μM ZnSO 4 , suggesting a highly specific interaction. The mechanism by which zinc interferes with the IFN:receptor interaction remains uncertain; however, we have ruled out an effect of zinc on IFN-λ3 disulfide bond formation. Type I and III IFNs bind to unique receptor complexes composed of IFN-α receptors IFNAR1/IFNAR2 and IFN-λ receptors IFNLR1/IL10RB, respectively, but signal via almost identical pathways. Consequently, zinc may act to reinforce the shared IFN signaling cascade by inhibiting protein tyrosine phosphatase enzymatic activity (152) . Following receptor engagement by IFNs, intracellular Janus protein tyrosine kinases Jak1 and Tyk2 become phosphorylated, which in turn phosphorylate STAT molecules to stimulate ISG expression. By dephosphorylating these key signaling molecules, a number of phosphatases have been shown to "put the brakes" on IFN signaling. Phosphatases tyrosineprotein phosphatase non-receptor type 6 (SHP1), type 11 (SHP2), and protein phosphatase 2A (PP2A) have all been shown to inhibit JAK-STAT phosphorylation (153) (154) (155) , and are all inhibited by zinc ions, predominantly in the nanomolar range (156) (157) (158) . Interestingly, PP2A can also inhibit the phosphorylation of IRF3, thus regulating antigen recognition by PRRs (159) . Conversely, the tumor suppressor phosphatase and tensin homologue (PTEN) stimulates IRF3 activation by removing inhibitory phosphorylation at Ser97 (160) , and is also inhibited by zinc at nanomolar concentrations (161) . Zinc inhibits numerous pro-and antiviral phosphatases, with the net effect on virus recognition and response being undefined, which clearly requires further study. To enable a highly controlled IFN response, negative regulators of IFN signaling are often ISGs. These include the suppressors of cytokine signaling (SOCS-1 and SOCS-3), which bind and inhibit JAK protein signaling, thus preventing signaling from numerous inflammatory (IL-6) and antiviral stimuli (162) . Interestingly, zinc-driven activation of the MTF-1 transcription factor can induce expression of SOCS-3 in HepG2 cells (163) . The zinc importer ZIP-14, which is responsible for zinc influx following inflammatory stimuli, was required for SOCS-3 expression, and may represent yet another zinc-mediated mechanism to limit the inflammatory response. Although the transporter responsible for hepatic zinc influx following IFN stimulation remains unknown, it is perceivable that ZIP-14 may drive zinc influx and subsequent SOCS-3 expression. Zinc deficiency caused by disease, age, and lifestyle factors: lessons from supplementation Zinc status is primarily determined by dietary zinc intake; however, additional factors such as dietary composition, alcohol intake, and disease state can significantly reduce zinc uptake and storage, or increase zinc excretion (164) . With respect to dietary composition, zinc supplementation as part of a meal can significantly reduce zinc absorption when compared to water-based solutions of zinc (164) . Moreover, dietary phytate, a natural chelator of zinc ions that is present in corn, rice, and cereals, can severely restrict zinc absorption (165) . Consequently, diets containing high phytate: zinc molar ratios, can result in zinc deficiency, even with adequate zinc intake. Unfortunately, rural diets in low-income nations are often zinc-poor and phytate-rich because of a dietary reliance on rice and vegetables. Aged individuals are also significantly more susceptible to zinc deficiency, increasing their likelihood of acquiring lifethreatening viral infections (166) . Ex vivo, zinc supplementation has been shown to improve leukocyte IFN-α production (167) and to reduce mononuclear cell TNF production (168) . Year-long supplementation with 45 mg elemental zinc/d in elderly subjects (aged 55-87 y), has also demonstrated a dramatic reduction in the incidence of infection as well as plasma oxidative stress markers (168) . Alcoholism can stimulate severe zinc deficiency developed via numerous sociological and physiological mechanisms, with factors including but not limited to 1) increased urinary zinc excretion (169) , 2) reduced zinc intake (poor diet) (170) , 3) reduced zinc absorption (171) , and 4) and a reduction in hepatic zinc stores (172) . Alcohol also stimulates microbial dysbiosis and gastrointestinal permeability (173), a phenotype that can increase the likelihood of viral infection in the gut (174) . Importantly, dietary zinc supplementation can improve intestinal barrier dysfunction as a result of alcohol and microbial infection (175, 176) . As previously discussed, zinc deficiency is common among chronic infections such as HPV, HCV, and HIV (113, 123) . Consequently, a number of studies have examined the effects of zinc supplementation on antiviral immunity, inflammation, and treatment response. As described above, zinc supplementation can improve HCV treatment response and liver inflammation caused by chronic infection. In addition, long-term zinc treatment over 7 y has been shown to reduce the risk of hepatocellular carcinoma progression in chronic HCV patients, as assessed by multivariate analysis, compared to controls (P < 0.05) (105) . Zinc supplementation has also been assessed as an adjunct therapy to antiretroviral administration in patients with HIV. One study reported a 4-fold reduction in the rate of immune failure, as well as decreased diarrhea in patients treated with zinc compared to controls (P < 0.05 for both groups) (124) . A more recent study revealed an increase in CD4 + T cell count in patients treated with a combination of zinc and antiretroviral therapy, compared to patients on antiretroviral therapy alone (P < 0.05) (177) . Taken together, these data indicate that zinc deficiency is associated with greater disease activity in the context of chronic viral infection. Oral zinc supplementation may act in a synergistic manner when co-administered with antiviral therapy and contribute to improved clinical outcomes. Zinc supplementation during vaccination strategies has provided an opportunity to examine the role of zinc in the humoral response to viruses. A particular focus has been applied to the effect of zinc supplementation on rotavirus vaccination because of the high rate of mortality associated with childhood diarrhea in developing countries. Unfortunately, although zinc deficiency is associated with increased risk of rotavirus gastroenteritis (178), it does not greatly increase the development of humoral immunity followed by vaccination (rotarix), as defined by seroconversion rate (179) . Nonetheless, a pooled analysis of randomized trials performed in 2000, demonstrated that zinc supplementation shortens the length of diarrheal episodes and reduced the rate of treatment failure or death by 42% in zinc-deficient children (180) . Comparable studies of supplementation with zinc before vaccination have produced similar disappointing results. Zinc supplementation did not improve seroconversion following administration of the oral poliovirus vaccine in infants (181) , nor did it improve the immunological response to HBV (182) or influenza vaccination (183) in the elderly. Although there remains little evidence that zinc improves viral vaccination responses, a small number of studies suggest that zinc may improve antibody titers and antibacterial responses to pneumococcus (184) and cholera infections (185) . The tight regulation of zinc homeostasis both systemically and intracellularly indicates that zinc plays an essential role in human health. Although zinc is a component of ∼10% of the human proteome, zinc in different forms (free compared with protein-bound) can stimulate a variety of signaling events, including the antiviral response. In vitro studies suggest that free zinc may possess potent antiviral effects, and are supported by trials of creams, lozenges, and supplements with high free zinc content. Moreover, zinc-binding proteins such as the metallothioneins may possess antiviral roles, although their specific function remains uncertain. Nonetheless, zinc treatment applied at a therapeutic dose and in the right form has the potential to drastically improve the clearance of both chronic and acute viral infections, as well as their accompanying pathologies and symptoms. Consequently, the role of zinc as an antiviral can be separated into 2 categories: 1) zinc supplementation implemented to improve the antiviral response and systemic immunity in patients with zinc deficiency, and 2) zinc treatment performed to specifically inhibit viral replication or infection-related symptoms (75, 78-82, 83, 85-91, 95-101, 103, 104) . Zinc as an antiviral 705 Zinc metabolism in patients with the syndrome of iron deficiency anemia, hepatosplenomegaly, dwarfism, and hypogonadism The human transcription factors A bioinformatics view of zinc enzymes Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting Dietary calcium and zinc deficiency risks are decreasing but remain prevalent Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease Zinc and immune function: the biological basis of altered resistance to infection Measuring picomolar intracellular exchangeable zinc in PC-12 cells using a ratiometric fluorescence biosensor Single and three-color flow cytometry assay for intracellular zinc ion availability in human lymphocytes with Zinpyr-1 and double immunofluorescence: relationship with metallothioneins Genetically encoded FRET sensors to monitor intracellular Zn 2+ homeostasis The physiological, biochemical, and molecular roles of zinc transporters in zinc homeostasis and metabolism The risk of copper deficiency in patients prescribed zinc supplements Metal limitation and toxicity at the interface between host and pathogen Mycobacterial p(1)-type ATPases mediate resistance to zinc poisoning in human macrophages Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children Role of Zn 2+ ions in host-virus interactions Regulation of cellular zinc balance as a potential mechanism of EVERmediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses Zn 2+ -induced IL-8 expression involves AP-1, JNK, and ERK activities in human airway epithelial cells Mucosal human papillomaviruses encode four different E5 proteins whose chemistry and phylogeny correlate with malignant or benign growth The carcinogenicity of human papillomavirus types reflects viral evolution Metallothioneins: emerging modulators in immunity and infection Mammalian metallothioneins: properties and functions Metallothionein and zinc transporter expression in circulating human blood cells as biomarkers of zinc status: a systematic review Metal responsive transcription factor 1 (MTF-1) regulates zinc dependent cellular processes at the molecular level Transcriptional and posttranscriptional regulation of interferoninduced gene expression in human cells Zinc is a potent and specific inhibitor of IFN-λ3 signalling The human genome browser at UCSC Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells Gene expression patterns in dendritic cells infected with measles virus compared with other pathogens Impact of influenza A virus infection on the proteomes of human bronchoepithelial cells from different donors Increased metallothionein gene expression, zinc, and zinc-dependent resistance to apoptosis in circulating monocytes during HIV viremia The antiviral role of zinc and metallothioneins in hepatitis C infection Metallothionein is induced and trace element balance changed in target organs of a common viral infection Zinc is a potent inhibitor of the apoptotic protease, caspase-3-a novel target for zinc in the inhibition of apoptosis Metallothionein is a potential negative regulator of apoptosis Cellular zinc status regulates cytomegalovirus major immediateearly promoter Zinc-induced activation of the human cytomegalovirus major immediate-early promoter is mediated by metallothionein and nuclear factor-κB Recent advances on viral manipulation of NF-κB signaling pathway Zinc ionophores pyrithione inhibits herpes simplex virus replication through interfering with proteasome function and NF-κB activation Abrogation of nuclear factor-κB activation is involved in zinc inhibition of lipopolysaccharide-induced tumor necrosis factor-α production and liver injury Zinc-suppressed inflammatory cytokines by induction of A20-mediated inhibition of nuclear factor-κB Zinc-induced NF-κB inhibition can be modulated by changes in the intracellular metallothionein level The NS5A protein of hepatitis C virus is a zinc metalloprotein A diverse range of gene products are effectors of the type I interferon antiviral response Reference values for the trace elements copper, manganese, selenium, and zinc in the serum/plasma of children, adolescents, and adults The mechanism of the antiherpetic activity of zinc-sulfate Zinc-buffering capacity of a eukaryotic cell at physiological pZn Insights into Zn 2+ homeostasis in neurons from experimental and modeling studies Zinc ion availability-the determinant of efficacy in zinc lozenge treatment of common colds Selective inhibition of herpes simplex virus type 1 DNA polymerase by zinc ions Effect of zinc ions on synthesis of herpes simplex virus type 2-induced polypeptides Zinc salts inactivate clinical isolates of herpes simplex virus in vitro Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine Herpes genitalis-topical zinc sulfate: an alternative therapeutic and modality Complexes of zinc with picolinic and aspartic acids inactivate free varicella-zoster virions Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture Characterization of the large picornaviral polypeptides produced in the presence of zinc ion Processing of mengovirus precursor polypeptides in the presence of zinc ions and sulfhydryl compounds Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections Effect of zinc and other chemical agents on foot-and-mouth-disease virus replication Inhibition of foot and mouth disease virus and procapsid synthesis by zinc ions Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli Zinc is a negative regulator of hepatitis C virus RNA replication Zinc inhibition of renin and the protease from human immunodeficiency virus type 1 Inhibition of HIV-1 infection by zinc group metal compounds Mechanism of HIV reverse transcriptase inhibition by zinc formation of a highly stable enzyme-(primer-template) complex with profoundly diminished catalytic activity Zinc induces apoptosis on cervical carcinoma cells by p53-dependent and -independent pathway Effect of zinc salts on respiratory syncytial virus replication Zinc ions inhibit replication of rhinoviruses Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides Biochemical characterization of rhinovirus RNA-dependent RNA polymerase Membrane fusion activity of Semliki Forest virus in a liposomal model system: specific inhibition by Zn 2+ ions Identification of a specific region in the E1 fusion protein involved in zinc inhibition of Semliki Forest virus fusion Inhibition of Sindbis virus-replication by zinc ions Antiviral activity of zinc salts against transmissible gastroenteritis virus in vitro Inhibition of vaccinia virus growth by zinc ions-effect on early RNA and thymidine kinase synthesis Inhibition of vaccinia virus maturation by zincchloride Characterization of vaccinia virus-DNA topoisomerase-I expressed in Escherichia c oli High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation A randomized double-blind placebo-controlled clinical trial of two strengths of topical zinc sulfate solution against recurrent herpes simplex Effect of treatment with zinc gluconate or zinc acetate on experimental and natural colds Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study Zinc gluconate and the common cold-a controlled clinical-study Zinc gluconate lozenges for treating the common cold-a randomized, double-blind, placebo-controlled study Randomized, doublemasked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptoms in allergy-tested subjects Duration of symptoms and plasma cytokine levels in patients with the common cold treated with zinc acetate-a randomized, double-blind, placebo-controlled trial Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial Topical zinc sulphate solution for treatment of viral warts Evaluation of oral zinc sulfate effect on recalcitrant multiple viral warts: a randomized placebocontrolled clinical trial Oral zinc sulfate for unresponsive cutaneous viral warts: too good to be true? A doubleblind, randomized, placebo-controlled trial The clinical effectiveness of intralesional injection of 2% zinc sulfate solution in the treatment of common warts Laryngeal papillomatosis treated by oral zinc sulphate Benefit of oral zinc supplementation as an adjunct to zidovudine (Azt) therapy against opportunistic infections in AIDS Effect of zinc on the immune status of zinc-depleted AIDS related complex patients Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebocontrolled trial Zinc supplementation to HIV-1-infected pregnant women: effects on maternal anthropometry, viral load, and early mother-to-child transmission Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin Efficacy of zinc administration in patients with hepatitis C virus-related chronic liver disease Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin PDTC inhibits picornavirus polyprotein processing and RNA replication by transporting zinc ions into cells Zinc lozenges as cure for the common cold-a review and hypothesis Zinc lozenges may shorten the duration of colds: a systematic review Effect of antioxidants on apoptosis induced by influenza virus infection: inhibition of viral gene replication and transcription with pyrrolidine dithiocarbamate Inhibition of the particle-associated RNAdependent RNA polymerase activity of influenza viruses by chelating agents The epidemiology of acute and chronic hepatitis C The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-α to hepatitis C patients Assembly and entry mechanisms of Semliki Forest virus Class II fusion protein of alphaviruses drives membrane fusion through the same pathway as class I proteins The ligand environment of zinc stored in vesicles Achieving HIV-1 control through RNAdirected gene regulation Inhibition of RNA-dependent DNA polymerase of Rous sarcoma virus by thiosemicarbazones and several cations Specific effect of zinc ions on DNApolymerase activity of avian myeloblastosis virus Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein Serum zinc concentration and C-reactive protein in individuals with human immunodeficiency virus infection: the POsitive Living with HIV (POLH) study Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults Zinc status in human immunodeficiency virus type 1 infection and illicit drug use Micronutrient supplementation in adults with HIV infection An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1 Worldwide burden of cancer attributable to HPV by site, country and HPV type The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets Systemic treatments for cutaneous warts: a systematic review Zinc deficiency in patients with persistent viral warts A pilot study to investigate the treatment of cervical human papillomavirus infection with zinc-citrate compound (CIZAR ® ) A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV Zinc signals and immunity Microbial sensing by toll-like receptors and intracellular nucleic acid sensors Interferon-λ: immune functions at barrier surfaces and beyond Differential regulation of TLR-dependent MyD88 and TRIF signaling pathways by free zinc ions ZIP8 regulates host defense through zinc-mediated inhibition of NF-κB IκB kinase-α is critical for interferon-α production induced by toll-like receptors 7 and 9 Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways IKKε and TBK1 are essential components of the IRF3 signaling pathway Inhibition of NF-κB signaling by A20 through disruption of ubiquitin enzyme complexes A20 is a potent inhibitor of TLR3-and Sendai virus-induced activation of NF-κB and ISRE and IFN-β promoter Negative regulation of the retinoic acid-inducible gene Iinduced antiviral state by the ubiquitin-editing protein A20 A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection TLR signals posttranscriptionally regulate the cytokine trafficking mediator sortilin Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis Zinc mediated dimer of human interferon-α 2b revealed by X-ray crystallography Zinc potentiates the antiviral action of human IFN-α tenfold Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent Phosphotyrosyl-protein phosphatase-specific inhibition by Zn-2+ Protein phosphatase 2A impairs IFNα-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway Differential regulation of the α/β interferon-stimulated Jak/STAT pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1 Zinc binds to and directly inhibits protein phosphatase 2A in vitro Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling Fluctuations of cellular, available zinc modulate insulin signaling via inhibition of protein tyrosine phosphatases adaptor protein deactivates transcription factor IRF3 and limits type I interferon signaling The tumor suppressor PTEN has a critical role in antiviral innate immunity PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation SOCS proteins, cytokine signalling and immune regulation Regulation of hepatic suppressor of cytokine signaling 3 by zinc Dietary factors influencing zinc absorption Adaptation in human zinc absorption as influenced by dietary zinc and bioavailability Infants and elderlies are susceptible to zinc deficiency Zinc supplementation reconstitutes the production of interferon-α by leukocytes from elderly persons Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress A study of zinc metabolism in alcoholic cirrhosis Nutritional intake of hazardous drinkers and dependent alcoholics in the UK Zinc absorption in alcoholics using Zn-65 Dysregulation of hepatic zinc transporters in a mouse model of alcoholic liver disease The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction Human intestinal barrier function in health and disease Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice Enteric protein loss and intestinal permeability changes in children during acute shigellosis and after recovery-effect of zinc supplementation Low plasma zinc levels and immunological responses to zinc supplementation in HIVinfected patients with immunological discordance after antiretroviral therapy Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: a randomized, factorial design, placebo-controlled study among Indian infants Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial The effect of zinc sulfate on immunologic response to recombinant hepatitis B vaccine in elderly Effect of zinc or zinc plus arginine supplementation on antibody titre and lymphocyte subsets after influenza vaccination in elderly subjects: a randomized controlled trial Immunization with the heptavalent pneumococcal conjugate vaccine in Bangladeshi infants and effects of zinc supplementation Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine The authors' responsibilities were as follows-SR and GA designed the review, all authors performed the study selection, all authors read and approved the final manuscript.